-
INOpulse therapy for PH associated with COPD to enter phase 2b trial in US
Bellerophon Therapeutics announced that it is moving forward with a planned Phase 2b trial that will investigate INOpulse as a therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), following an agreement with the U.S. Food and Drug Administration regarding the study’s design.
Read the fully story here: INOpulse Therapy for PH Associated with COPD to Enter Phase 2b Trial in US
Are you familiar with INOpulse therapy? What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.